PITTSBURGH

匹兹堡

,

，

Oct. 30, 2026

2026年10月30日

/PRNewswire/ --

/美通社/ --

Viatris Inc.

晖致公司

('Viatris') (Nasdaq:

（晖致）（纳斯达克：

VTRS

VTRS

), a global healthcare company, today announced that Peach Purchaser Sub Inc. ('Purchaser'), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the 'Shares'), of Pacira BioSciences, Inc.

），一家全球医疗健康公司，今日宣布，Viatris 的全资子公司 Peach Purchaser Sub Inc.（“收购方”）已启动一项要约收购，以购买 Pacira BioSciences, Inc. 所有已发行且流通在外的普通股，每股面值 0.001 美元（“股份”）。

('Pacira') (Nasdaq: .

（Pacira）（纳斯达克：

PCRX

PCRX

), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 30, 2026 (as it may be amended or supplemented from time to time, the 'Offer to Purchase'), and the accompanying Letter of Transmittal (the 'Letter of Transmittal' and, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, the 'Offer')..

），以现金方式按每股36.50美元的价格支付（扣除适用的预提税款，且不计利息），具体条款及条件见日期为2026年10月30日的《购买要约》（该文件可能不时修订或补充，统称“《购买要约》”）以及随附的《递交函》（该《递交函》与《购买要约》及其他相关材料一起，可能不时修订或补充，统称“本次要约”）。

The Offer is being made pursuant to the Agreement and Plan of Merger, dated Oct. 8, 2026, by and among Viatris, Purchaser and Pacira (as it may be amended or supplemented from time to time, the 'Merger Agreement'). The Merger Agreement provides, among other things, that as soon as practicable following the consummation of the Offer, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the General Corporation Law of the State of Delaware, as amended (the 'DGCL'), Purchaser will be merged with and into Pacira (the 'Merger') with Pacira continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Viatris.

本次要约是依据Viatris、买方与Pacira于2026年10月8日签署的《合并协议与计划》（经不时修订或补充，下称“《合并协议》”）作出的。《合并协议》规定，除其他事项外，在要约完成之后，在符合《合并协议》所列条款和条件以及经修订的《特拉华州普通公司法》（“DGCL”）的前提下，买方将与Pacira合并并并入Pacira（下称“本次合并”），Pacira将作为本次合并中的存续公司，并成为Viatris的全资子公司。

By virtue of the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (subject to certain exceptions set forth in the Merger Agreement) will be converted into the right to receive $36.50 per Share, in cash, net of applicable withholding taxes and without interest.

凭借合并，每股在合并生效时间之前发行且流通的股份（受合并协议中规定的某些例外情况限制）将转换为获得每股36.50美元现金的权利，扣除适用的预扣税款且不计利息。

The Merger will be governed by Section 251(h) of the DGCL and, as a result, does not require a vote of Pacira's stockholders. Purchaser may not provide any 'subsequent offering period' for the Offer (within the meaning of Rule 14d-11 promulgated under the Securities Exchange Act of 1934 (as amended, the 'Exchange Act')) without the prior written consent of Pacira..

本次合并将受《特拉华州普通公司法》第251(h)条的管辖，因此，无需经过Pacira股东的投票表决。未经Pacira事先书面同意，购买方不得为要约提供任何“后续要约期”（该术语含义见根据经修订的《1934年证券交易法》（以下简称“《交易法》”）颁布的第14d-11条规则）。

Pacira's board of directors (the 'Pacira Board') has published a Solicitation/Recommendation Statement on Schedule 14D-9 (the 'Schedule 14D-9') and filed the Schedule 14D-9 with the U.S. Securities and Exchange Commission (the 'SEC') on Oct. 30, 2026. The Schedule 14D-9 includes, among other things, the unanimous recommendation of the Pacira Board that Pacira's stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer..

Pacira董事会（“Pacira董事会”）已发布Schedule 14D-9征集/推荐声明（“Schedule 14D-9”），并于2026年10月30日向美国证券交易委员会（“SEC”）提交了该Schedule 14D-9。Schedule 14D-9其中包括（但不限于）Pacira董事会一致建议Pacira股东接受要约，并根据要约将其股份 tender 给买方。

The Offer and withdrawal rights will expire one minute following 11:59 p.m., Eastern Time, on Nov. 16, 2026, unless the Offer is extended or earlier terminated (such date, or any subsequent date to which the expiration of the Offer is extended in accordance with the terms of the Merger Agreement, the 'Expiration Date').

除非要约被延长或提前终止，否则要约及撤回权将于2026年11月16日东部时间晚上11点59分过后一分钟失效（该日期，或根据合并协议条款将要约到期日延长至的任何后续日期，均称为“到期日”）。

.

。

The Offer may be extended as provided in the Merger Agreement. Any extension, delay, termination or amendment of the Offer will be followed, as promptly as practicable, by a public announcement thereof, and such announcement, in the case of an extension, will be made no later than 9 a.m., Eastern Time, on the next business day after the previously scheduled Expiration Date.

要约可根据合并协议的规定予以延长。任何要约的延长、延迟、终止或修订，均将在切实可行的情况下尽快发布公开公告；若要约延期，则该公告不得晚于原定到期日之后的下一个工作日上午9点（东部时间）发布。

Shares that are tendered pursuant to the Offer may be withdrawn at any time prior to the Expiration Date and, if such Shares have not yet been accepted for payment by Purchaser pursuant to the Offer (the time of such acceptance, the 'Offer Acceptance Time'), may also be withdrawn at any time after Dec.

根据要约 tendered 的股份可在到期日之前的任何时间撤回，并且，如果该等股份尚未被买方根据要约接受付款（该等接受的时间为“要约接受时间”），则也可在12月之后的任何时间撤回。

29, 2026, which is the 60th day after the date of the commencement of the Offer. Upon the terms and subject to the conditions of the Offer, Purchaser will promptly accept for payment at the Offer Acceptance Time, and pay for all Shares that are validly tendered (and not validly withdrawn) pursuant to the Offer as promptly as practicable after the Offer Acceptance Time..

2026年，即要约开始之日起的第60天。根据要约的条款并受其条件的约束，买方将在要约接受时间 promptly 接受付款，并在要约接受时间之后尽快为所有根据要约有效提交（且未有效撤回）的股份支付款项。

Purchaser's obligation to pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to certain conditions, including, among others, (a) the Minimum Condition (as defined below), (b) the expiration or termination of the waiting period (or any extension thereof) applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and (c) the absence of any legal restraint that prohibits or makes .

购买人根据要约支付已有效提交（且未有效撤回）的股份之义务，须满足若干条件，其中包括但不限于：(a) 最低条件（定义见下文）；(b) 经修订的《1976年哈特-斯科特-罗迪诺反托拉斯改进法》项下适用于本要约的等待期（或其任何延期）届满或终止；以及 (c) 不存在任何禁止或使得...的法律限制。

illegal

非法

the consummation of the Offer or the Merger. The 'Minimum Condition' means that, prior to the Expiration Date, there will have been validly tendered (and not validly withdrawn) in the Offer a number of Shares that, together with the Shares then owned by Purchaser and its affiliates (as such term is defined in Section 251(h)(6) of the DGCL), represents at least one Share more than 50% of the total number of Shares issued and outstanding at the time of expiration of the Offer, excluding for these purposes Shares tendered pursuant to guaranteed delivery procedures that have not yet been 'received' by the 'depository' (as such terms are defined in Section 251(h)(6) of the DGCL).

要约或合并的完成。“最低条件”是指，在到期日之前，已有效 tendered（且未有效撤回）的要约股份数量，连同买方及其关联公司（该术语定义见《特拉华州普通公司法》第251(h)(6)条）当时持有的股份，合计至少比要约到期时已发行及流通在外股份总数的50%多出一股；为此目的，不包括根据担保交付程序 tendered 但尚未被“存管机构”（这些术语定义见《特拉华州普通公司法》第251(h)(6)条）“收到”的股份。

The Offer is not subject to a financing condition..

本次要约不以融资条件为前提。

The documentation relating to the Offer (including the Offer to Purchase, the Letter of Transmittal and the Schedule 14D-9) can be accessed at the following link:

与本次要约相关的文件（包括《购买要约》、《提交函》和 Schedule 14D-9 表格）可通过以下链接访问：

https://www.shareholdermaterials.com/pcrx2026/

https://www.shareholdermaterials.com/pcrx2026/

.

。

The Offer to Purchase, the related Letter of Transmittal and the Schedule

收购要约、相关的递交函及附表

14D-9 (which contains the recommendation of the Pacira Board and the reasons therefor) contain important information. Pacira's stockholders should carefully read all documents in their entirety before any decision is made with respect to the Offer.

14D-9 文件（其中包含 Pacira 董事会的建议及其理由）载有重要信息。Pacira 的股东在就本次要约作出任何决定之前，应仔细阅读所有文件的全文。

The information required to be disclosed by paragraph (d)(1) of Rule 14d-6 promulgated under the Exchange Act is contained in the Offer to Purchase and is incorporated herein by reference.

《交易法》下颁布的第14d-6条(d)(1)款要求披露的信息包含在《购买要约》中，并在此通过引用并入。

Pacira has provided Purchaser with its stockholder list, security position listings and certain other information regarding the beneficial owners of Shares for the purpose of disseminating the Offer to holders of Shares. Purchaser will send the Offer to Purchase, the related Letter of Transmittal and other related documents to record holders of Shares and to brokers, dealers, commercial banks, trust companies and other nominees whose names appear on the stockholder list or, if applicable, who are listed as participants in a clearing agency's security position listing for subsequent transmittal to beneficial owners of Shares..

Pacira 已向购买方提供其股东名册、证券头寸清单以及关于股份受益所有人的某些其他信息，以便向股份持有人分发要约。购买方将向股份登记持有人以及出现在股东名册上的经纪人、交易商、商业银行、信托公司及其他名义持有人，或（如适用）在清算机构证券头寸清单中列为参与者的经纪人、交易商、商业银行、信托公司及其他名义持有人，发送收购要约、相关的递交函及其他相关文件，以便随后转递给股份的受益所有人。

Questions or requests for assistance may be directed to Innisfree M&A Incorporated, who is serving as the information agent (the 'Information Agent'), at the address and telephone numbers set forth below. Requests for copies of the Offer to Purchase, the related Letter of Transmittal and other tender offer materials may be directed to the Information Agent or to brokers, dealers, commercial banks or trust companies.

如有任何疑问或需要协助，可联系担任信息代理（“信息代理”）的 Innisfree M&A Incorporated，联系地址和电话号码如下。索取《购买要约》、相关的《递交函》及其他要约收购材料的请求，可向信息代理或经纪商、交易商、商业银行或信托公司提出。

Such copies will be furnished promptly at Purchaser's expense..

此类副本将及时提供，费用由买方承担。

INNISFREE M&A INCORPORATED

悦诗风吟并购股份有限公司

500 Fifth Avenue, 21st Floor

第五大道500号，21层

New York, NY 10110

纽约州纽约市 10110

Shareholders May Call:

股东可致电：

(866) 239-1760 (TOLL-FREE from the U.S. and Canada), or

(866) 239-1760（从美国和加拿大拨打免费），或

+1 (412) 232-3651 (from other countries)

+1 (412) 232-3651（从其他国家拨打）

Banks and Brokers May Call Collect:

银行和经纪商可能会要求收回款项：

(212) 750-5833

(212) 750-5833

About Viatris

关于晖致

Viatris Inc.

晖致公司

(Nasdaq:

（纳斯达克：

VTRS

VTRS

) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure.

）是一家全球医疗健康公司，其使命是赋能全球人民在生命的每个阶段都能享有更健康的生活。我们以智慧和决心果断行动，满足全球患者的需求。无论是研发新药、努力维持所需疗法的韧性供应，还是追求大胆创新，我们都致力于提供规模有效且持久耐用的解决方案。

We're purpose-built to make an impact with a broad portfolio that spans generics, value-added medicines, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and .

我们专为创造影响力而打造，拥有涵盖仿制药、增值药物、成熟品牌药以及针对重大未满足需求领域的创新药的多元化产品组合。公司总部位于美国，并在匹兹堡、上海和印度海得拉巴设有全球中心。请访问 viatris.com 了解更多信息。

investor.viatris.com

investor.viatris.com

, and connect with us on

，并在以下平台关注我们

LinkedIn

领英

,

，

Instagram

Instagram

,

，

YouTube

YouTube

and

和

X

X

.

。

Forward-Looking Statements

前瞻性陈述

This communication contains 'forward-looking statements'. Such forward-looking statements may include, without limitation, statements about the transaction (in which, among other things, Viatris, through its wholly-owned subsidiary, has commenced the Offer to acquire all of the outstanding Shares of Pacira and, following the consummation of the Offer, for such wholly-owned subsidiary of Viatris to be merged with and into Pacira), the expected timetable for completing the proposed transaction, the anticipated benefits and synergies of the proposed transaction, the ability to complete the transaction or to satisfy the various closing conditions, future opportunities for Viatris or Pacira and either of their products and any other statements regarding Viatris' or Pacira's future operations, strategic initiatives and priorities, restructuring activities, financial or operating results, capital allocation, dividend policy and payments, share repurchases, debt ratio and covenants, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, imperatives, competitions, commitments, confidence in future results, efforts to create, enhance or otherwise unlock value, other expectations, plans, trends, outlooks, projections, prospects and targets for future periods, and any other statements that are not historical facts.

本通讯包含“前瞻性陈述”。此类前瞻性陈述可能包括但不限于以下内容的陈述：关于本次交易（其中，除其他事项外，Viatris 通过其全资子公司已启动要约收购 Pacira 所有流通股份，并在该要约收购完成后，将 Viatris 的该全资子公司与 Pacira 合并并并入 Pacira）；完成拟议交易的预期时间表；拟议交易的预期效益和协同效应；完成交易或满足各项交割条件的能力；Viatris 或 Pacira 及其各自产品的未来机会；以及有关 Viatris 或 Pacira 未来运营、战略举措与优先事项、重组活动、财务或经营业绩、资本配置、股息政策与支付、股份回购、债务比率与契约、预期业务量、未来收益、计划活动、预期增长、市场机会、战略、必要行动、竞争、承诺、对未来业绩的信心、创造、提升或以其他方式释放价值的努力、其他预期、计划、趋势、展望、预测、前景和未来期间的目标，以及任何非历史事实的陈述。

Forward-looking statements may often be identified by the use of words such as 'will', 'may', 'can', 'could', 'should', 'would', 'project', 'believe', 'anticipate', 'expect', 'plan', 'estimate', 'forecast', 'potential', 'pipeline', 'intend', 'continue', 'target', 'seek' and variations of these words or comparable words..

前瞻性陈述通常可通过使用“将”、“可能”、“能够”、“可以”、“应当”、“会”、“预测”、“相信”、“预期”、“期望”、“计划”、“估计”、“预报”、“潜在”、“管线”、“打算”、“继续”、“目标”、“寻求”等词语以及这些词语的变体或类似词语来识别。

Because forward-looking statements inherently involve known and unknown risks and uncertainties, actual future results, levels of activity, performance or achievements may differ materially from those expressed or implied by such forward-looking statements, and there can be no assurance that estimates, assumptions and expectations will prove to have been correct.

由于前瞻性陈述 inherently 涉及已知和未知的风险与不确定性，实际的未来结果、活动水平、业绩或成就可能与这些前瞻性陈述所明示或暗示的内容存在重大差异，且无法保证相关估计、假设和预期将被证实为正确。

Factors that could cause or contribute to such differences include, but are not limited to: the ability of Viatris and Pacira to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; the ability of Viatris and Pacira to consummate the proposed transaction; the conditions to the completion of the proposed transaction (including, but not limited to, the Minimum Condition) not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; the possibility that competing offers may be made; the possibility that Viatris may be unable to achieve the intended or expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected timeframe or at all or to successfully integrate Viatris and Pacira; Viatris' or Pacira's failure to achieve expected or targeted future financial and operating performance and results; the possibility that Viatris or Pacira may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives and priorities; actions and decisions of healthcare and pharmaceutical regulators; changes in relevant laws, regulations and policies and/or the application or implementation thereof, includin.

可能导致或促成此类差异的因素包括但不限于：晖致（Viatris）和帕西拉（Pacira）能否满足关于拟议交易的时间安排、完成情况及会计和税务处理的预期；晖致和帕西拉能否完成拟议交易；拟议交易的完成条件（包括但不限于最低条件）未能在预期时间内或根本未能得到满足或豁免；拟议交易所需的监管批准未能在预期条款下、按预期时间表或根本未能获得；可能出现竞争性报价的可能性；晖致可能无法在预期时间内或根本无法实现与拟议交易相关的预期或预计收益、协同效应和运营效率，或无法成功整合晖致和帕西拉；晖致或帕西拉未能实现预期的或目标未来的财务和经营业绩及成果；晖致或帕西拉可能无法实现其战略举措和优先事项的预期收益，或未能实现与之相关的预期目标或前景；医疗保健和药品监管机构的行为和决策；相关法律、法规和政策的变化及其适用或执行情况的变动，包括。

For more detailed information on the risks and uncertainties associated with Viatris and Pacira, see the risks described in Part I, Item 1A of their respective Annual Reports on Form 10-K for the year ended Dec. 31, 2025, and their other filings with the SEC. You can access their respective filings with the SEC through the SEC website at .

有关与Viatris和Pacira相关的风险和不确定性的更详细信息，请参阅它们在截至2025年12月31日的年度Form 10-K报告第一部分第1A项中描述的风险，以及它们向美国证券交易委员会（SEC）提交的其他文件。您可以通过SEC网站访问它们各自提交的文件。

www.sec.gov

www.sec.gov

or through their respective websites, and each of Viatris and Pacira strongly encourages you to do so. Viatris routinely posts information that may be important to investors on its website at

或通过其各自的网站，Viatris 和 Pacira 均强烈建议您这样做。Viatris 在其网站上定期发布可能对投资者具有重要意义的信息，网址为

investor.viatris.com

investor.viatris.com

, and uses this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). The contents of each of Viatris's and Pacira's websites are not incorporated into this communication or their respective filings with the SEC.

，并将该网站地址作为向公众广泛、非排他性地披露重大信息的手段，以符合美国证券交易委员会（SEC）《公平披露条例》（Reg FD）的要求。Viatris 和 Pacira 各自网站的内容均未纳入本沟通文件或它们各自向 SEC 提交的文件中。

Each of Viatris and Pacira undertakes no obligation to update any statements herein for revisions or changes after the date of this communication other than as required by law..

Viatris 和 Pacira 均不承担更新本沟通文件中任何陈述的义务，以反映在本沟通文件日期之后的修订或变更，除非法律另有要求。

Important Information about the Transaction and Where to Find It

关于交易的重要信息及查询方式

This communication is for informational purposes only and it is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell Shares, nor is it a substitute for the tender offer materials that Viatris, Purchaser or Pacira have filed with the SEC.  Viatris has filed a Tender Offer Statement on Schedule TO, containing the Offer to Purchase, the Letter of Transmittal and other related tender offer documents, with the SEC, and Pacira has filed the Solicitation/Recommendation Statement on Schedule 14D-9 relating to the Offer with the SEC.  The Offer is only being made pursuant to the Offer to Purchase and the exhibits filed with respect thereto (including the Letter of Transmittal) and other related tender offer documents filed as a part of the Schedule TO, which contain the full terms and conditions of the Offer.

本沟通文件仅供信息参考，既不构成购买股份的建议或要约，也不构成出售股份要约的招揽，亦不能替代Viatris、买方或Pacira向美国证券交易委员会（SEC）提交的要约收购材料。Viatris已向SEC提交了包含购买要约、转让函及其他相关要约收购文件的TO表格要约收购声明，Pacira已就本次要约向SEC提交了14D-9表格征求/推荐声明。本次要约仅依据购买要约及其附件（包括转让函）以及作为TO表格一部分提交的其他相关要约收购文件作出，上述文件载有本次要约的全部条款和条件。

.

。

Pacira's stockholders are strongly advised to read the tender offer materials (including the Offer to Purchase, the Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement on Schedule

强烈建议 Pacira 的股东阅读要约收购材料（包括《购买要约》、《提交函》及某些其他要约收购文件）以及附表中的征集/推荐声明

14D-9 carefully and in their entirety, as they may be amended or supplemented from time to time, because they contain important information about the Offer that Pacira's stockholders should consider prior to making any decisions with respect to the Offer, including the terms and conditions of the Offer..

14D-9 文件（包括其不时作出的修订或补充）应予以仔细、完整地阅读，因为这些文件载有关于本次要约的重要信息，Pacira 的股东在就本次要约作出任何决定之前，包括在考虑本次要约的条款和条件时，应当审慎考量这些信息。

The Offer to Purchase, the Letter of Transmittal and other related tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of Pacira at no expense to them

《购买要约》、《递交函》及其他相关要约收购文件，以及附表14D-9中的征求/推荐声明，将免费发送给Pacira的所有股东。

.

。

The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9, and other related documents filed with the SEC are available for free at the website maintained by the SEC at

在美国证券交易委员会（SEC）维护的网站上，可免费查阅根据TO表格提交的要约收购声明、根据14D-9表格提交的征求/推荐声明以及其他向美国证券交易委员会提交的相关文件，网址为

www.sec.gov

www.sec.gov

and can be accessed at the following link:

并可从以下链接访问：

https://www.shareholdermaterials.com/pcrx2026/

https://www.shareholdermaterials.com/pcrx2026/

.

。

In addition, a copy of the Offer to Purchase, the Letter of Transmittal and other related tender offer documents may be obtained free of charge by directing a request to Viatris at

此外，可通过向晖致（Viatris）提出请求，免费获取《购买要约》、《递交函》及其他相关要约收购文件。

[email protected]

[email protected]

.  A copy of the Solicitation/Recommendation Statement on Schedule 14D-9 also may be obtained free of charge by directing a request to Pacira at

. 也可通过向 Pacira 提出请求，免费获取 Schedule 14D-9 中的要约/推荐声明副本，联系方式为

[email protected]

电子邮件地址：[email protected]

.

。

SOURCE Viatris Inc.

来源：晖致公司